Skip to content
‹ Back to IndustriesHealthcare

The Use of AI in Cancer Screenings

Medical imaging, an integral part of the cancer screening process, continues to experience rapid, year-over-year growth. Unfortunately, available radiologists cannot keep pace with the demand for their services fueled by the continued growth in cancer screening. New solutions are in desperate need to support diagnosis and improve workflows. Can AI play an important role in…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Intel on MarketScale.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Medical imaging, an integral part of the cancer screening process, continues to experience rapid, year-over-year growth. Unfortunately, available radiologists cannot keep pace with the demand for their services fueled by the continued growth in cancer screening. New solutions are in desperate need to support diagnosis and improve workflows. Can AI play an important role in cancer screenings today and in the future? That’s what Health and Life Sciences at the Edge’s Tyler Kern wants to find out, and Intel’s Business Development and Sales Lead, Ryan Kim, and Lunit’s Director of INSIGHT Marketing, Jonathan Yang, have answers. 

The disparity between the growing need for cancer screenings and the radiologists available to do the work can lead to missed early detection of cancers on chest X-rays and mammograms. Yang says this situation can create a big problem. “Regarding mammography, a high number of screenings can be read as false-positive, meaning that only a single digit percent of those recalled are retested,” he explains. “So, this is where AI can come in. AI isn’t here to replace radiologists, but it is here to support them, especially regarding cancer screening.” Yang sees many potential benefits AI can provide in assisting cancer screenings for patients, physicians, and medical institutions.

AI-driven solutions can reduce physicians’ reading time. Yang states, “This allows physicians to spend more time on the hard and tough cases. It also enables early detection of disease.”

Integrating AI into the cancer screening process is a seamless process today. Yang says there are two ways to integrate AI into the diagnostic imaging workflow. The first is when an image is acquired, and the second is during the image interpretation process. In both cases, Luni partners with companies with imaging platforms to make the integration seamless for healthcare institutions.

The utilization of Intel’s OpenVINO™ Toolkit assists in processing images quickly and minimizing the time from X-ray imaging to diagnosis. With OpenVINO™ technology, diagnostics can run on a CPU-only mode of operations, which reduces the cost of operations while delivering on the imaging speed physicians need. 

Learn more about AI-enabled cancer screening solutions by connecting with Ryan Kim and Jonathan Yang on LinkedIn or visit Intel Health and Life Sciences and Lunit’s websites. 

Subscribe to this channel on Apple Podcasts, Spotify, and Google Podcasts to hear more from the Intel Network and Edge Group.

Intel

Part of this channel

Intel

Silicon and AI platforms powering enterprise and edge compute.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

QinFlow's new pressure bag device skips scheduled calibration and preventive maintenance

QinFlow's new pressure bag device skips scheduled calibration and preventive maintenance

QinFlow's PressSure is a battery-powered device that holds standard pressure bags at one of three fixed preset pressures during blood or IV fluid infusions.

  • 01The claims so far are design claims and an award shortlist; the signal worth watching is whether QinFlow or early adopters publish in-service data on reinflation time saved.

Oct 1, 2026

BedConnect’s Lindsey Joseph on matching post-acute care to patient needs

BedConnect’s Lindsey Joseph on matching post-acute care to patient needs

On I Don’t Care, BedConnect founder Lindsey Joseph and Kevin Stevenson discuss the limits of broad post-acute referrals. Their proposal is to match clinical needs, payer coverage and available beds before presenting options. CMS guidance and AHRQ discharge resources provide independent context; they do not establish BedConnect’s clinical outcomes.

  • 01BedConnect proposes matching clinical needs, payer coverage and bed availability before presenting post-acute options; this is the company’s approach, not independently validated outcome evidence.
  • 02CMS discharge-planning guidance emphasizes patient goals, treatment preferences and relevant provider quality and resource-use data.
  • 03Readmission comparisons need a defined patient group, time window and source; the interview’s roughly one-quarter/fourteen-day estimate has not been independently verified.

Sep 29, 2026

Rock Health: $7.4B went into digital health in H1 2026, and 20 rounds took 45%

Rock Health: $7.4B went into digital health in H1 2026, and 20 rounds took 45%

Rock Health: U.S. digital health startups raised $7.4 billion across 244 deals in H1 2026, up from $6.4 billion on 245 deals in H1 2025. The rebound is concentrated. Nineteen companies raised 20 $100 million-plus rounds that captured 45% of capital.

  • 01In H1 2026, 19 companies raised 20 mega-deals of $100 million or more, representing 45% of all capital invested, according to Rock Health.
  • 02According to Rock Health, the firm stopped labeling startups as “AI-enabled,” saying the technology is now too widespread for the label to be meaningful.

Sep 24, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512